Zaprinast
(Synonyms: 2-(2-丙氧苯基)-8-氮杂次黄嘌呤,M&B 22948) 目录号 : GC12909Zaprinast是一种磷酸二酯酶抑制剂，主要靶向PDE5和PDE6，IC50值分别为0.8µM和0.15µM。
Cas No.:37762-06-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Zaprinast is a phosphodiesterase inhibitor that targets PDE5 and PDE6, with the IC50 values of 0.8µM and 0.15µM, respectively[1]. Zaprinast acts as an agonist for rat GPR35, with a geometric mean EC50 value of 16nM[2]. Through inhibition of phosphodiesterases, especially PDE5 and PDE6, Zaprinast increases intracellular cGMP levels, which modulates downstream signaling pathways such as protein kinase G (PKG) and cyclic nucleotide gated ion channels[3]. Zaprinast has been widely used in different animal models to regulate smooth muscle contraction and coronary artery relaxation[4].
In vitro, Zaprinast treatment for 48 hours significantly inhibited SK-N-MC cell proliferation with an IC50 value of 3.3µM[5]. Zaprinast (100µM) treatment for 1 hour significantly activated ERK1/2, p38 MAPK, JNK, NFκB and PI3K/Akt signaling pathways in rat microglia[6]. Pretreatment of neonatal rat-derived astrocytes with 100μM Zaprinast for 1h significantly inhibited H2O2-induced lactate dehydrogenase release and cell death[7].
In vivo, Zaprinast treatment via intraperitoneal injection at a dose of 10mg/kg at 2 hours before and 24 and 48 hours after focal cryolesion of cortex significantly enhanced astrogliosis and reduced oxidative stress and cell death at 3 days after focal cryolesion in male Sprague-Dawley rats[8]. A single intraperitoneal injection of Zaprinast (30mg/kg) for 18 hours significantly improved glucose tolerance in diet-induced obese (DIO) mice[9].
References:
[1] Mackenzie A E, Milligan G. The emerging pharmacology and function of GPR35 in the nervous system[J]. Neuropharmacology, 2017, 113: 661-671.
[2] Taniguchi Y, Tonai-Kachi H, Shinjo K. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35[J]. FEBS letters, 2006, 580(21): 5003-5008.
[3] Halene T B, Siegel S J. PDE inhibitors in psychiatry–future options for dementia, depression and schizophrenia?[J]. Drug discovery today, 2007, 12(19-20): 870-878.
[4] Gibson A. Phosphodiesterase 5 inhibitors and nitrergic transmission—from zaprinast to sildenafil[J]. European journal of pharmacology, 2001, 411(1-2): 1-10.
[5] Giorgi M, Leonetti C, Citro G, et al. In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors[J]. Journal of neuro-oncology, 2001, 51(1): 25-31.
[6] Lee H S, Kwon S H, Ham J E, et al. Zaprinast activates MAPKs, NFκB, and Akt and induces the expressions of inflammatory genes in microglia[J]. International immunopharmacology, 2012, 13(3): 232-241.
[7] Choi J H, Kim D H, Yun I J, et al. Zaprinast inhibits hydrogen peroxide-induced lysosomal destabilization and cell death in astrocytes[J]. European journal of pharmacology, 2007, 571(2-3): 106-115.
[8] Pifarré P, Prado J, Giralt M, et al. Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury[J]. Journal of neurochemistry, 2010, 112(3): 807-817.
[9] Hodges W T, Jarasvaraparn C, Ferguson D, et al. Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice[J]. Journal of Biological Chemistry, 2022, 298(2): 101554.
Zaprinast是一种磷酸二酯酶抑制剂，主要靶向PDE5和PDE6，IC50值分别为0.8µM和0.15µM[1]。Zaprinast可作为大鼠GPR35受体的激动剂，几何平均EC50值为16nM[2]。通过抑制磷酸二酯酶活性，Zaprinast能提高细胞内cGMP水平，进而调控蛋白激酶G(PKG)及环核苷酸门控离子通道等下游信号通路[3]。Zaprinast已广泛应用于多种动物模型中调节平滑肌收缩和冠状动脉舒张[4]。
在体外，Zaprinast处理48小时可显著抑制SK-N-MC细胞增殖，IC50值为3.3µM[5]。使用100µM的Zaprinast处理大鼠小胶质细胞1小时，能显著激活ERK1/2、p38 MAPK、JNK、NFκB和PI3K/Akt信号通路[6]。用100μM的Zaprinast预处理新生大鼠星形胶质细胞1小时，可显著抑制H2O2诱导的乳酸脱氢酶释放和细胞死亡[7]。
在体内，在雄性Sprague-Dawley大鼠皮层冷冻损伤前2小时及损伤后24、48小时分别腹腔注射10mg/kg剂量的Zaprinast，能增强冷冻损伤后3天的星形胶质细胞增生，并降低氧化应激和细胞死亡率[8]。对饮食诱导的肥胖(DIO)小鼠单次腹腔注射30mg/kg剂量的Zaprinast 18小时，可显著改善葡萄糖耐受性[9]。
| Cell experiment [1]: | |
Cell lines | SK-N-MC cells |
Preparation Method | SK-N-MC cells were cultured in Minimum Essential Medium (MEM) supplemented with non-essential amino acid (NEAA), sodium pyruvate (110mg/l), 10% foetal bovine serum, penicillin (5000IU/ml) and streptomycin (5mg/ml), at 37℃ in a humidified 5% CO2 atmosphere. Cultures were periodically tested for mycoplasma contamination and only negative cells were used for experiments. Cells were plated in 24-well trays at a density of 5×104 cells/well. Twenty-four hours later, Zaprinast was added at various concentration (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5µM). Forty-eight hours later the number of surviving cells was determined. |
Reaction Conditions | 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5µM; 48h |
Applications | Zaprinast treatment inhibited the cell viability of SK-N-MC cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | LS-Mpc2−/− mice |
Preparation Method | LS-Mpc2−/− mice were raised in a standard sterile environment, switched from standard diet to 60% high-fat diet at 7 to 8 weeks of age and tested 12 weeks later. Zaprinast was dissolved in 25% DMSO/75% saline and administered intraperitoneally at a dose of 30mg/kg 18 hours before the glucose tolerance test (GTT). |
Dosage form | 30mg/kg for once; i.p. |
Applications | Zaprinast treatment significantly improved glucose tolerance in LS-Mpc2−/− mice. |
References: | |
| Cas No. | 37762-06-4 | SDF | |
| 别名 | 2-(2-丙氧苯基)-8-氮杂次黄嘌呤,M&B 22948 | ||
| 化学名 | 5-(2-propoxyphenyl)-2H-[1,2,3]triazolo[4,5-d]pyrimidin-7(3H)-one | ||
| Canonical SMILES | O=C1N=C(C2=CC=CC=C2OCCC)N=C3NNN=C31 | ||
| 分子式 | C13H13N5O2 | 分子量 | 271.28 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 10 mg/ml | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6862 mL | 18.4311 mL | 36.8623 mL |
| 5 mM | 737.2 μL | 3.6862 mL | 7.3725 mL |
| 10 mM | 368.6 μL | 1.8431 mL | 3.6862 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet